Literature DB >> 2886162

Detection of HIV antigen and specific antibodies to HIV core and envelope proteins in sera of patients with HIV infection.

Y Z Cao, F Valentine, S Hojvat, J P Allain, P Rubinstein, M Mirabile, S Czelusniak, M Leuther, L Baker, A E Friedman-Kien.   

Abstract

The sera of well-characterized populations were examined for three markers of human immunodeficiency virus (HIV) infection; HIV antigen (HIV Ag), and antibodies to HIV envelope (gp41) and core (p24) proteins. Of 563 serum samples tested, 251 were from HIV-infected patients diagnosed as having AIDS manifested by opportunistic infections (AIDS-OI), AIDS-associated Kaposi's sarcoma (AIDS-KS), or AIDS-related complex (ARC). One hundred seventy-six specimens tested were from asymptomatic high-risk individuals, and 136 were from heterosexual control subjects or patients with non-AIDS-related disease. None of the 136 control individuals tested had HIV Ag or HIV antibodies to either p24 or gp41. Of the 427 HIV-seropositive individuals, 99% to 100% were positive for gp41 antibodies to HIV. In contrast, the seroprevalence of p24 antibodies to HIV varied from 23% to 83% and appeared to be inversely associated with the severity of the patients' clinical symptoms. When specimens were analyzed for the presence of HIV Ag, in seropositive individuals the prevalence rate for this marker was lowest (1.4%) in asymptomatic individuals and highest (50%) in the AIDS-OI diagnosed group. Also, 240 cases with AIDS-KS, AIDS-OI, and ARC and the group of asymptomatic high-risk individuals were analyzed for T helper/T lymphocytes (T4) cell number and T4/T8 ratio; only one (2.0%) HIV Ag-positive case showed a T4 cell number greater than 400 and a normal T4/T8 ratio. These studies appear to demonstrate a direct correlation between the presence of HIV Ag and the severity of clinical complications of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2886162

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease.

Authors:  N L Michael; M Vahey; D S Burke; R R Redfield
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

2.  Passive hemagglutination test for detection of antibodies to human immunodeficiency virus type 1 and comparison of the test with enzyme-linked immunosorbent assay and Western blot (immunoblot) analysis.

Authors:  M B Vasudevachari; K W Uffelman; T C Mast; R L Dewar; V Natarajan; H C Lane; N P Salzman
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

3.  Use of TrpE/Gag fusion proteins to characterize immunoreactive domains on the human immunodeficiency virus type 1 core protein.

Authors:  M G Windheuser; G E Tegtmeier; C Wood
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

4.  Inhibition of human immunodeficiency virus (HIV) replication by HIV-trans-activated alpha 2-interferon.

Authors:  D P Bednarik; J D Mosca; N B Raj; P M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

5.  Antibodies against the major core protein p24 of human immunodeficiency virus: relation to immunological, clinical and prognostic findings.

Authors:  B O Lindhardt; J Gerstoft; B Hofmann; G Pallesen; L Mathiesen; E Dickmeiss; K Ulrich
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

6.  Correlation of serum antigen and antibody concentration with clinical features in HIV infection.

Authors:  M Ellaurie; A Rubinstein
Journal:  Arch Dis Child       Date:  1991-02       Impact factor: 3.791

7.  Predictive value of the presence of P24 antigen in persons with antibodies to human immunodeficiency virus in Spain.

Authors:  M Leal; J A Pineda; E J Calderón; C Rey; E Lissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-03       Impact factor: 3.267

8.  Low-dose zidovudine in combination with either acyclovir or lymphoblastoid interferon-alpha in asymptomatic HIV-infected patients: a pilot study.

Authors:  R Weber; A Bonetti; J Jost; M W Vogt; B Spacey; W Siegenthaler; R Lüthy
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

9.  Comparison of an amplified enzyme-linked immunosorbent assay with procedures based on molecular biology for assessing human immunodeficiency virus type 1 viral load.

Authors:  P L Goldschmidt; A Devillechabrolle; Z Ait-Arkoub; J T Aubin
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

10.  Serological response in patients with chronic asymptomatic human immunodeficiency virus infection.

Authors:  B O Lindhardt; K Ulrich; P Kusk; B Hofmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-06       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.